{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"2.4","value":"1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"The start and stop times of daratumumab infusion will be tracked during infusion acceleration.","dispersionType":"Full Range","groups":[{"description":"Patients received daratumumab 16 mg/kg IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Daratumumab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Total Daratumumab Infusion Time","type":"PRIMARY","unitOfMeasure":"hours"}